Makena Follows Avastin’s Path With US FDA Hearing On Accelerated Approval Withdrawal
Executive Summary
Chief scientist Denise Hinton will decide the fate of Covis’ preterm birth prevention drug because acting commissioner Janet Woodcock has recused herself; CBER deputy director Celia Witten is tapped to serve as presiding officer at the hearing, which will be only the second of its kind under accelerated approval regulations.
You may also be interested in...
US FDA’s Drugs Center Wins Round One In Makena Dispute With Covis On Document Production
Company is not entitled to CDER's unredacted materials or predecisional drafts and emails on the proposed withdrawal of accelerated approval. However, presiding officer Celia Witten sets a 24 January deadline for CDER’s document production and requests the center re-examine what materials from a medical policy council meeting can be released.
US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree
Jacqueline O’Shaughnessy takes over as acting chief scientist following Denise Hinton’s move to the surgeon general’s office; Hinton previously had been tapped by acting commissioner Janet Woodcock to make a final decision on the accelerated approval status of Covis' preterm birth prevention drug Makena.
Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use
A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.